# Kim Kelderman

> Kim Kelderman is the President and CEO of Bio-Techne Corporation, a global life science tools and diagnostics company headquartered in Minneapolis, Minnesota. With over 30 years of healthcare and life sciences experience, Kelderman rose through the ranks at Bio-Techne after joining in 2018 to lead the Diagnostics and Genomics segment, where he doubled the spatial biology business and commercialized the ExoDx Prostate test. A native of the Netherlands educated at Hogeschool Heerlen and Columbia Business School, he previously held executive roles at Thermo Fisher Scientific and Becton Dickinson. He became CEO on February 1, 2024, succeeding Chuck Kummeth.

- **Role:** President and CEO at Bio-Techne Corporation
- **Organizations:** Bio-Techne Corporation, CONMED Corporation, StatLab Medical Products, Thermo Fisher Scientific, Becton Dickinson, GeneOhm Sciences
- **From:** Netherlands
- **Nationality:** Dutch
- **Education:** Bachelor of Science, Hogeschool Heerlen (Zuyd University of Applied Sciences), Executive Education / MBA-level, Columbia Business School
- **Known for:** Appointed President and CEO of Bio-Techne Corporation effective February 1, 2024, Doubled revenue of Bio-Techne's spatial biology business (Advanced Cell Diagnostics) during tenure as segment president, Commercialized the ExoDx Prostate test, a liquid biopsy diagnostic for prostate cancer

## Career timeline

- **2005** — Vice President of Operations and General Manager of Canadian business at GeneOhm Sciences
- **2006** — GeneOhm Sciences acquired by Becton Dickinson; continued as senior segment leader managing global Blood Tubes (Vacutainer) business
- **~2006-2018** — Led three businesses of increasing scale at Thermo Fisher Scientific, most recently managing Platforms and Content of the Genetic Sciences Division (Applied Biosystems and Affymetrix brands)
- **2018-04** — Joined Bio-Techne as President, Diagnostics and Genomics Segment
- **2023-11** — Promoted to Chief Operating Officer at Bio-Techne
- **2024-02** — Appointed President and Chief Executive Officer of Bio-Techne Corporation; joined Board of Directors
- **2025-09** — Appointed to CONMED Corporation Board of Directors
- **2026-01** — Presented at J.P. Morgan Healthcare Conference representing Bio-Techne
- **2026-05** — Presented at Bank of America Securities Global Healthcare Conference

## Achievements

- Appointed President and CEO of Bio-Techne Corporation effective February 1, 2024
- Doubled revenue of Bio-Techne's spatial biology business (Advanced Cell Diagnostics) during tenure as segment president
- Commercialized the ExoDx Prostate test, a liquid biopsy diagnostic for prostate cancer
- Led successful acquisitions of Asuragen and Lunaphore at Bio-Techne
- Managed businesses with over $1 billion in annual revenue at Thermo Fisher Scientific
- Oversaw major brands Applied Biosystems and legacy Affymetrix at Thermo Fisher
- Appointed to CONMED Corporation Board of Directors (September 2025)
- Serves on Board of Directors of StatLab Medical Products
- Presented Bio-Techne at J.P. Morgan Healthcare Conference 2025 and 2026
- Helped Bio-Techne grow from $311M to over $1.1B in revenue over the past decade-plus

## Latest updates

- **2026-05** — Presented at Bank of America Securities 2026 Global Healthcare Conference
- **2026-03** — Presented at TD Cowen Health Care Conference discussing Bio-Techne's 50-year anniversary and strategic priorities
- **2026-01** — Presented at J.P. Morgan Healthcare Conference 2026
- **2025-09** — Appointed to CONMED Corporation Board of Directors
- **2025-01** — Presented at J.P. Morgan Healthcare Conference 2025
- **2024-02** — Became President and CEO of Bio-Techne Corporation

## Links

- Website: https://bio-techne.com
- LinkedIn: http://www.linkedin.com/in/kkelderman
- Twitter/X: https://x.com/keldermankim

---

Profile page: https://yespress.io/kim-kelderman
Published by YesPress — https://yespress.io
Last updated: 2026-05-16